Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Murlentamab in advanced gynecological cancer
NCT02978755Phase 1Completed
- Sponsor
- GamaMabs Pharma
- Start
- Jun 2016
- Primary completion
- Jun 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label trial of GM-102 in gynecologic cancer, Sex cord stromal tumor (SCST), epithelial ovarian cancer (EOC) and 1 more (3 arms), sponsored by GamaMabs Pharma. Primary endpoints: Incidence of Dose Limiting Toxicities at 4 weeks and Incidence of Serious Adverse Events and Treatment-Emergent Adverse Events at 1 year. Started Jun 2016; status: completed.
02
Drugs
GM-102
03
Conditions
gynecologic cancerSex cord stromal tumor (SCST)epithelial ovarian cancer (EOC)Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT02978755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02978755.